Published November 25, 2011 | Version v1
Journal article Metadata-only

Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines

Creators

  • 1. Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110 (United States)
  • 2. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO 63110 (United States)
  • 3. The Genome Institute at Washington University School of Medicine, St. Louis, MO 63108 (United States)
  • 4. Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 (United States)
  • 5. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110 (United States)

Description

New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines

Availability note (English)

Available from http://dx.doi.org/10.3390/cancers3044191; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763418

Additional details

Identifiers

URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763418;
DOI
10.3390/cancers3044191;

Publishing Information

Journal Title
Cancers (Basel)
Journal Volume
3
Journal Issue
4
Journal Page Range
p. 4191-4211
ISSN
2072-6694

INIS

Country of Publication
Switzerland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47001832
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANTIGENS; DECISION MAKING; DNA SEQUENCING; DRUGS; LICENSES; MAMMARY GLANDS; NEOPLASMS; VACCINES
Descriptors DEC
BODY; DISEASES; GLANDS; ORGANS; STRUCTURAL CHEMICAL ANALYSIS

Optional Information

Copyright
Copyright (c) 2011 by the authors
Notes
PMCID: PMC3763418; PMID: 24213133; PUBLISHER-ID: cancers-03-04191; OAI: oai:pubmedcentral.nih.gov:3763418; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).